VIKING GLOBAL INVESTORS LP's Net Worth

$23.3 Million

Who is VIKING GLOBAL INVESTORS LP?

VIKING GLOBAL INVESTORS LP has an estimated net worth of $23.3 Million. This is based on reported shares across multiple companies, which include FIRST DATA CORP, Wayfair Inc., Amylyx Pharmaceuticals, Inc., Adaptive Biotechnologies Corp, Zentalis Pharmaceuticals, LLC, RayzeBio, Inc., Editas Medicine, Inc., Inhibrx, Inc., Arbutus Biopharma Corp, Myovant Sciences Ltd., Roivant Sciences Ltd., PROCEPT BioRobotics Corp, BridgeBio Pharma, Inc., 4D Molecular Therapeutics, Inc., Rallybio Corp, Ginkgo Bioworks Holdings, Inc., APi Group Corp, FIGS, Inc., Urovant Sciences Ltd., Axovant Sciences Ltd., Frazier Lifesciences Acquisition Corp, STANDARD BIOTOOLS INC., and Inhibrx Biosciences, Inc..

SEC CIK

VIKING GLOBAL INVESTORS LP's CIK is 0001103804

Past Insider Trading and Trends

2015 was VIKING GLOBAL INVESTORS LP's most active year for acquiring shares with 12 total transactions. VIKING GLOBAL INVESTORS LP's most active month to acquire stocks was the month of January. 2016 was VIKING GLOBAL INVESTORS LP's most active year for disposing of shares, totalling 6 transactions. VIKING GLOBAL INVESTORS LP's most active month to dispose stocks was the month of March. 2014 saw VIKING GLOBAL INVESTORS LP paying a total of $430,238.88 for 146,761 shares, this is the most they've acquired in one year. In 2016 VIKING GLOBAL INVESTORS LP cashed out on 30,638,952 shares for a total of $0.00, their largest year based on trade value.